Array BioPharma (ARRY) MEK Deal 'Favorable', BMO Capital Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
Go back to Array BioPharma (ARRY) MEK Deal 'Favorable', BMO Capital Says
December 3, 2014 4:03 PM EST
Array Biopharma (NASDAQ: ARRY) announced that it has reached a definitive agreement with Novartis International Pharmaceutical Ltd. (NYSE: NVS) to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials. This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline PLC (GSK) on April 22, 2014, which are expected in the first half of 2015, and remain subject to regulatory approval. Array had previously granted Novartis worldwide exclusive rights to develop and commercialize binimetinib under a 2010 License Agreement, which will terminate and be... More
December 3, 2014 4:01 PM EST
Array Biopharma, Inc. (NASDAQ: ARRY) Halted, News Pending
...
More
